INT8111

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.81
First Reported 1991
Last Reported 2010
Negated 1
Speculated 0
Reported most in Abstract
Documents 32
Total Number 32
Disease Relevance 19.53
Pain Relevance 2.54

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (EPO) extracellular space (EPO) aging (EPO)
extracellular region (EPO)
Anatomy Link Frequency
liver 2
precursor cells 2
blood 2
neurons 2
pituicytes 2
EPO (Homo sapiens)
Pain Link Frequency Relevance Heat
carbamazepine 1 99.72 Very High Very High Very High
Somatostatin 9 99.24 Very High Very High Very High
medulla 107 98.40 Very High Very High Very High
anesthesia 14 95.60 Very High Very High Very High
Inflammation 26 95.16 Very High Very High Very High
Pain 13 90.96 High High
antagonist 4 83.68 Quite High
metalloproteinase 1 83.52 Quite High
cytokine 37 81.44 Quite High
rheumatoid arthritis 2 81.28 Quite High
Disease Link Frequency Relevance Heat
Hypothermia 1 100.00 Very High Very High Very High
Uremia 2 99.84 Very High Very High Very High
Injury 83 99.46 Very High Very High Very High
Hypoxia 79 99.40 Very High Very High Very High
Cancer 216 99.20 Very High Very High Very High
Anaemia 335 99.08 Very High Very High Very High
Aplasia 17 98.84 Very High Very High Very High
Myelodysplastic Syndromes 56 98.78 Very High Very High Very High
Renal Failure 23 98.76 Very High Very High Very High
Cerebral Palsy 4 98.68 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
We show that in response to axonal injury, periaxonal Schwann cells release erythropoietin (EPO), which via EPO receptor binding on neurons, prevents axonal degeneration.
Localization (release) of erythropoietin in neurons associated with injury
1) Confidence 0.81 Published 2004 Journal Ann. Neurol. Section Abstract Doc Link 15470751 Disease Relevance 0.61 Pain Relevance 0.06
We show that in response to axonal injury, periaxonal Schwann cells release erythropoietin (EPO), which via EPO receptor binding on neurons, prevents axonal degeneration.
Localization (release) of EPO in neurons associated with injury
2) Confidence 0.81 Published 2004 Journal Ann. Neurol. Section Abstract Doc Link 15470751 Disease Relevance 0.61 Pain Relevance 0.06
Therapy with TNFalpha exerts a suppressive effect on EPO secretion in these patients.
Localization (secretion) of EPO
3) Confidence 0.80 Published 2001 Journal J. Biol. Regul. Homeost. Agents Section Abstract Doc Link 11860225 Disease Relevance 0.89 Pain Relevance 0.10
The following mechanisms can be distinguished: a resistance of the erythroid precursor cells (BFU-e, CFU-e) to erythropoietin, an inappropriately decreased renal erythropoietin secretion for a given haemoglobin value and alterations of the iron metabolism leading to a functional iron deficiency.
Localization (secretion) of erythropoietin in precursor cells associated with anaemia
4) Confidence 0.80 Published 1999 Journal Praxis Section Abstract Doc Link 10067375 Disease Relevance 1.35 Pain Relevance 0.18
The following mechanisms can be distinguished: a resistance of the erythroid precursor cells (BFU-e, CFU-e) to erythropoietin, an inappropriately decreased renal erythropoietin secretion for a given haemoglobin value and alterations of the iron metabolism leading to a functional iron deficiency.
Localization (secretion) of erythropoietin in precursor cells associated with anaemia
5) Confidence 0.80 Published 1999 Journal Praxis Section Abstract Doc Link 10067375 Disease Relevance 1.36 Pain Relevance 0.18
Deliberate self-administration of recombinant human erythropoietin (rHuEpo) in a patient without anemia has never been documented.
Localization (self-administration) of erythropoietin associated with anaemia
6) Confidence 0.75 Published 1993 Journal Am J Emerg Med Section Abstract Doc Link 8240567 Disease Relevance 0.38 Pain Relevance 0.07
Deliberate self-administration of recombinant human erythropoietin (rHuEpo) in a patient without anemia has never been documented.
Localization (self-administration) of rHuEpo associated with anaemia
7) Confidence 0.75 Published 1993 Journal Am J Emerg Med Section Abstract Doc Link 8240567 Disease Relevance 0.38 Pain Relevance 0.07
Efficacy of epoetin beta
Localization (Efficacy) of epoetin beta
8) Confidence 0.75 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2697520 Disease Relevance 0.34 Pain Relevance 0.03
PRCA has been primarily associated with the use of a specific epoetin alfa preparation (Eprex®, Janssen-Cilag Ltd, Bucks, UK) in patients receiving hemodialysis.73


Localization (preparation) of epoetin associated with aplasia
9) Confidence 0.75 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2697520 Disease Relevance 0.76 Pain Relevance 0
We have confirmed that renal cortical blood flow (RCBF) is significantly decreased by recombinant human erythropoietin (EPO).
Localization (decreased) of EPO in blood
10) Confidence 0.74 Published 1999 Journal Urol. Res. Section Abstract Doc Link 10550517 Disease Relevance 0.29 Pain Relevance 0.08
We have confirmed that renal cortical blood flow (RCBF) is significantly decreased by recombinant human erythropoietin (EPO).
Localization (decreased) of erythropoietin in blood
11) Confidence 0.74 Published 1999 Journal Urol. Res. Section Abstract Doc Link 10550517 Disease Relevance 0.29 Pain Relevance 0.08
At 17 h, pericapillary Epo is absent and, instead, localized to scattered neurons [35].
Neg (absent) Localization (localized) of Epo in scattered neurons
12) Confidence 0.74 Published 2009 Journal Malar J Section Body Doc Link PMC2785829 Disease Relevance 0.68 Pain Relevance 0.15
The use of epoetin alfa and granulocyte colony-stimulating factor generally is not recommended or required for treating neutropenia and anemia, adverse effects from pegINF/RBV.
Localization (use) of epoetin in granulocyte associated with neutropenia and anaemia
13) Confidence 0.73 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2731021 Disease Relevance 2.02 Pain Relevance 0.10
Finally, no difference in the number and size of colonies was observed after 14 days when CD34+ cells from control subjects, PV patients or PFCP patients were cultured on soft agar in the presence of 3 U/mL EPO (data not reported).
Localization (presence) of EPO associated with myelodysplastic syndromes
14) Confidence 0.72 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2916842 Disease Relevance 0.35 Pain Relevance 0
Erythropoietin (EPO) is a sialoglycoprotein hormone secreted primarily by the mature kidneys in response to tissue hypoxia and/or red cell mass decrease.
Localization (secreted) of Erythropoietin associated with hypoxia
15) Confidence 0.71 Published 2005 Journal BMC Nephrol Section Body Doc Link PMC1164417 Disease Relevance 0.26 Pain Relevance 0
Erythropoietin (EPO) is a sialoglycoprotein hormone secreted primarily by the mature kidneys in response to tissue hypoxia and/or red cell mass decrease.
Localization (secreted) of EPO associated with hypoxia
16) Confidence 0.71 Published 2005 Journal BMC Nephrol Section Body Doc Link PMC1164417 Disease Relevance 0.26 Pain Relevance 0
The effect of chronic treatment with recombinant human erythropoietin (rHuEPO) on GH secretion in uremic patients undergoing continuous ambulatory peritoneal dialysis (CAPD) is not known.
Localization (secretion) of erythropoietin associated with renal failure and uremia
17) Confidence 0.69 Published 1992 Journal Adv Perit Dial Section Abstract Doc Link 1361819 Disease Relevance 0.61 Pain Relevance 0.06
The effect of chronic treatment with recombinant human erythropoietin (rHuEPO) on GH secretion in uremic patients undergoing continuous ambulatory peritoneal dialysis (CAPD) is not known.
Localization (secretion) of rHuEPO associated with renal failure and uremia
18) Confidence 0.69 Published 1992 Journal Adv Perit Dial Section Abstract Doc Link 1361819 Disease Relevance 0.61 Pain Relevance 0.06
Relationship between Epo, EpoR and CD131 immunostaining and indicators of hypoxia
Localization (Relationship) of Epo associated with hypoxia
19) Confidence 0.69 Published 2009 Journal Malar J Section Body Doc Link PMC2785829 Disease Relevance 1.24 Pain Relevance 0.19
In the current study, Epo receptors were rarely observed on axons and Epo positive glia were not distributed around axonal fibre tracts.
Localization (receptors) of Epo
20) Confidence 0.69 Published 2009 Journal Malar J Section Body Doc Link PMC2785829 Disease Relevance 1.20 Pain Relevance 0.30

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox